Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of LRIG3 mRNA] | CTD | PMID:31150632 | 1,2-dimethylhydrazine | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of LRIG3 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | multiple interactions | ISO | Lrig3 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LRIG3 mRNA | CTD | PMID:22206623 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of LRIG3 mRNA | CTD | PMID:26496021 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Lrig3 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of LRIG3 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of LRIG3 mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of LRIG3 mRNA | CTD | PMID:23152189 | acrylamide | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Acrylamide results in decreased expression of LRIG3 mRNA | CTD | PMID:32763439 | aflatoxin B1 | increases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of LRIG3 mRNA | CTD | PMID:19770486 | aflatoxin B1 | decreases methylation | ISO | LRIG3 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of LRIG3 gene | CTD | PMID:27153756 | all-trans-retinoic acid | multiple interactions | ISO | Lrig3 (Mus musculus) | 6480464 | [bisphenol F co-treated with Tretinoin] results in decreased expression of LRIG3 mRNA | CTD | PMID:30951980 | aristolochic acid A | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of LRIG3 mRNA | CTD | PMID:33212167 | benzo[a]pyrene | increases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of LRIG3 mRNA | CTD | PMID:19770486 | benzo[a]pyrene | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of LRIG3 mRNA | CTD | PMID:21632981 | benzo[b]fluoranthene | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in decreased expression of LRIG3 mRNA | CTD | PMID:26377693 | bisphenol A | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of LRIG3 mRNA | CTD | PMID:25047013 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of LRIG3 mRNA | CTD | PMID:30816183 | bisphenol A | decreases methylation | ISO | Lrig3 (Mus musculus) | 6480464 | bisphenol A results in decreased methylation of LRIG3 promoter | CTD | PMID:27312807 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of LRIG3 mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of LRIG3 mRNA | CTD | PMID:26496021 | bisphenol F | multiple interactions | ISO | Lrig3 (Mus musculus) | 6480464 | [bisphenol F co-treated with Tretinoin] results in decreased expression of LRIG3 mRNA | CTD | PMID:30951980 | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of LRIG3 mRNA | CTD | PMID:33453195 | calcitriol | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Calcitriol results in decreased expression of LRIG3 mRNA | CTD | PMID:16002434 | carbon nanotube | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | clofibrate | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Clofibrate results in decreased expression of LRIG3 mRNA | CTD | PMID:23811191 | cobalt dichloride | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | cobaltous chloride results in decreased expression of LRIG3 mRNA | CTD | PMID:19320972 | cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of LRIG3 mRNA | CTD | PMID:24386269 | copper atom | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of LRIG3 mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of LRIG3 mRNA | CTD | PMID:20971185 | copper(II) sulfate | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of LRIG3 mRNA | CTD | PMID:19549813 | cyclosporin A | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of LRIG3 mRNA | CTD | PMID:27989131 | decabromodiphenyl ether | increases expression | EXP | | 6480464 | decabromobiphenyl ether results in increased expression of LRIG3 mRNA | CTD | PMID:23914054 | diethyl maleate | decreases expression | EXP | | 6480464 | diethyl maleate results in decreased expression of LRIG3 mRNA | CTD | PMID:21161181 | dorsomorphin | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of LRIG3 mRNA | CTD | PMID:29803840 | folic acid | multiple interactions | ISO | Lrig3 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LRIG3 mRNA | CTD | PMID:22206623 | fonofos | increases methylation | ISO | LRIG3 (Homo sapiens) | 6480464 | Fonofos results in increased methylation of LRIG3 promoter | CTD | PMID:22847954 | formaldehyde | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of LRIG3 mRNA | CTD | PMID:20655997 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of LRIG3 mRNA | CTD | PMID:33387578 | lead(0) | affects expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Lead affects the expression of LRIG3 mRNA | CTD | PMID:28903495 | leflunomide | increases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | leflunomide results in increased expression of LRIG3 mRNA | CTD | PMID:28988120 | lipopolysaccharide | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LRIG3 mRNA | CTD | PMID:35811015 | melphalan | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Melphalan results in decreased expression of LRIG3 mRNA | CTD | PMID:22363485 | methamphetamine | increases expression | EXP | | 6480464 | Methamphetamine results in increased expression of LRIG3 mRNA | CTD | PMID:19564919 | nickel sulfate | increases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | nickel sulfate results in increased expression of LRIG3 mRNA | CTD | PMID:22714537 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of LRIG3 mRNA | CTD | PMID:25729387 | paracetamol | affects expression | ISO | Lrig3 (Mus musculus) | 6480464 | Acetaminophen affects the expression of LRIG3 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of LRIG3 mRNA | CTD | PMID:33387578 | paracetamol | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of LRIG3 mRNA | CTD | PMID:29067470 | parathion | increases methylation | ISO | LRIG3 (Homo sapiens) | 6480464 | Parathion results in increased methylation of LRIG3 promoter | CTD | PMID:22847954 | pirinixic acid | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of LRIG3 mRNA | CTD | PMID:23811191 | potassium chromate | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of LRIG3 mRNA | CTD | PMID:22714537 | quercetin | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Quercetin results in decreased expression of LRIG3 mRNA | CTD | PMID:21632981 | resorcinol | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | resorcinol results in decreased expression of LRIG3 mRNA | CTD | PMID:22623647 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of LRIG3 mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | terbufos | increases methylation | ISO | LRIG3 (Homo sapiens) | 6480464 | terbufos results in increased methylation of LRIG3 promoter | CTD | PMID:22847954 | testosterone | increases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Testosterone deficiency results in increased expression of LRIG3 mRNA | CTD | PMID:33848595 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of LRIG3 mRNA] | CTD | PMID:31150632 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of LRIG3 mRNA | CTD | PMID:30723492 and PMID:31150632 | tetracycline | increases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Tetracycline results in increased expression of LRIG3 mRNA | CTD | PMID:16917069 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of LRIG3 mRNA | CTD | PMID:34492290 | titanium dioxide | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of LRIG3 mRNA | CTD | PMID:23409001 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of LRIG3 mRNA | CTD | PMID:25729387 | toxaphene | increases expression | EXP | | 6480464 | Toxaphene results in increased expression of LRIG3 mRNA | CTD | PMID:23153324 | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of LRIG3 mRNA | CTD | PMID:33387578 | trichostatin A | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of LRIG3 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG3 mRNA | CTD | PMID:27188386 | trimellitic anhydride | decreases expression | ISO | Lrig3 (Mus musculus) | 6480464 | trimellitic anhydride results in decreased expression of LRIG3 mRNA | CTD | PMID:19042947 | valproic acid | decreases methylation | ISO | LRIG3 (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of LRIG3 gene | CTD | PMID:29154799 | valproic acid | increases expression | ISO | Lrig3 (Mus musculus) | 6480464 | Valproic Acid results in increased expression of LRIG3 mRNA | CTD | PMID:24896083 | valproic acid | multiple interactions | ISO | LRIG3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG3 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | LRIG3 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of LRIG3 mRNA | CTD | PMID:23179753 more ... | |